 |
Peregrine's Novel PS-Targeting Technology Platform to Be Highlighted at The New York Academy of Sciences Symposium on May 1, 2012
Apr 26, 2012
|
17.6 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 04/26/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that its phosphatidylserine (PS)-targeting technology platform and its lead drug candidate, bavituximab, will be highlighted at a symposium hosted by The New York Academy of Sciences. The event entitled "Phosphatidylserine Asymmetry and Cel...
|
|
Promising Clinical Data in Breast and Liver Cancers Further Expand the Broad Therapeutic Potential of Peregrine's Bavituximab
Apr 4, 2012
|
23.5 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 04/04/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today highlighted positive data from two Phase I investigator-sponsored trials (IST) and one precl...
|
|
Peregrine Launches PS-Targeting Clinical Imaging Program
Apr 3, 2012
|
19.3 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 04/03/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that it has launched a program for its experimental phosphatidylserine (PS)-target...
|
|
AVID Bioservices Highlights Antibody Engineering, Expression and Bioassay Expertise at AACR
Apr 2, 2012
|
17.9 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 04/02/12 --
Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today presented data at the Annual Meeting of the American Association of Cancer Research (AACR), demonstrating its ability to make genetic modifications to monoclonal antibodies, resulting in enhanced Fc related function...
|
|
Promising Data Presented at AACR Further Support New Lung Cancer Treatment Combination as Well as Ongoing Studies of Peregrine's Bavituximab
Apr 2, 2012
|
22.0 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 04/02/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today highlighted data(1) presented at the Annual Meeting of the American Association for Cancer Research (AACR...
|
|
Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ
Mar 28, 2012
|
14.5 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 03/28/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, announced that it received today a notice from The NASDAQ Stock Market indicating that the company's minimum bid...
|
|
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2012 Financial Results and Recent Developments
Mar 9, 2012
|
28.3 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 03/09/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced financial results for the third quarter ended January 31, 2012 of fiscal year (FY) 2012 and pr...
|
|
Peregrine Reports Data From Phase II Front-Line Lung Cancer Trial
Mar 9, 2012
|
19.8 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 03/09/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced top-line overall response rate (ORR) and current median progression free survival (PFS) estimates from its phase II trial comparing bavituximab plus carboplatin and paclitaxel versus carboplatin and paclitaxel alone in patients with front-l...
|
|
Peregrine to Report Third Quarter Fiscal Year 2012 Financial Results After Market on March 9, 2012
Mar 1, 2012
|
14.8 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 03/01/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the third quarter of the fiscal year 2012 on March 9, 2...
|
|
Peregrine Announces Seven Abstracts Accepted for Presentation at AACR 2012 Annual Meeting
Mar 1, 2012
|
22.6 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 03/01/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that data from seven clinical and preclinical studies investigating the company's lead clinica...
|
|
Peregrine Announces Participation at Upcoming Investor Conferences in March
Feb 27, 2012
|
14.8 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 02/27/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the following two investor conferences in...
|
|
Avid Bioservices to Present at IBC's Antibody Development and Production Conference
Feb 23, 2012
|
16.6 KB |
|
| |
TUSTIN, CA and SAN DIEGO, CA -- (MARKET WIRE) -- 02/23/12 --
Avid Bioservices, Inc., a leading provider of integrated biomanufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it will present two posters at IBC's 28th International Antibody Development & Production Conference to be held ...
|
|
Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST
Feb 9, 2012
|
14.2 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 02/09/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, its president and chief executive officer, is scheduled to present at the 14...
|
|
Peregrine Provides Update on HCV Clinical Program
Dec 29, 2011
|
19.3 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 12/29/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chro...
|
|
Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments
Dec 12, 2011
|
29.2 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 12/12/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the second quarter ended October 31, 2011 of fiscal year (FY) 2012 and prov...
|
|
Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial
Dec 6, 2011
|
18.9 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 12/06/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced preliminary results from a randomized Phase II trial showing a 50% improvement in overall tumor response rates (ORR) in non-small cell lung cancer (NSCLC) patients. Patients treated with bavituximab plus carboplatin and paclitaxel currentl...
|
|
Peregrine to Report Second Quarter Fiscal Year 2012 Financial Results After Market on December 12, 2011
Dec 5, 2011
|
14.8 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 12/05/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the second quarter of the fiscal year 2012 on December ...
|
|
Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial
Nov 22, 2011
|
19.6 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 11/22/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced 23.2 month median overall survival (OS) from a single-arm Phase II trial evaluating bavituximab i...
|
|
Peregrine to Present at Lazard Healthcare Conference November 15, 2011 at 11:30 AM EST
Nov 8, 2011
|
15.3 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 11/08/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the 8th Annual Lazard Capital Markets Healthcare Conference in New York, NY on...
|
|
Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012
Oct 6, 2011
|
18.8 KB |
|
| |
TUSTIN, CA -- (MARKET WIRE) -- 10/06/11 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment and randomization of 121 patients in a double-blind, placebo-control...
|
|
|
